World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
20473
World Ranking
1914
National Ranking
936

Olivera J. Finn publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Olivera J. Finn sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 314 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Olivera J. Finn D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Olivera J. Finn sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2019 - Distinguished Fellows of the American Association of Immunologists (AAI)
  • 2016 - AAI Lifetime Achievement Award, American Association of Immunologists
  • 2016 - American Association of Immunologists Lifetime Achievement Award

Overview

Olivera J. Finn is affiliated with the University of Pittsburgh in the United States. Their research spans multiple fields including immunology, microbiology, medicine, and biochemistry, genetics, and molecular biology. Within these broader areas, their work focuses on subfields such as immunology, oncology, molecular biology, epidemiology, and biomedical engineering.

The scientist's research emphasizes several key topics including immunotherapy and immune responses, cancer immunotherapy and biomarkers, immune cells in cancer, glycosylation and glycoproteins research, vaccines and immunoinformatics approaches, CAR-T cell therapy research, and immune cell function and interaction.

Among their recent papers are:

  • Beneficial autoimmunity improves cancer prognosis, 2021, Nature Reviews Clinical Oncology
  • Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting, 2023, Nature Communications
  • Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma, 2023, Clinical Cancer Research
  • Cancer vaccines, 2022, Cancer Cell
  • Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn's Disease, 2020, Journal of Clinical Gastroenterology

Olivera J. Finn has collaborated frequently with several coauthors, including Camille M. Jacqueline, Pamela Beatty, Robert E. Schoen, Jason Lohmueller, and Jonathan S. Minden.

The scientist's work has been published repeatedly in several venues such as Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), Frontiers in Immunology, Regular and Young Investigator Award Abstracts, and Cancer Immunology Research.

Recognition for their contributions includes several awards from the American Association of Immunologists (AAI), notably the Distinguished Fellows award in 2019 and the Lifetime Achievement Award in 2016.

Best Publications

  • The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

    Martin A. Cheever;Martin A. Cheever;James P. Allison;Andrea S. Ferris;Olivera J. Finn

  • Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

    Jan Schmielau;Olivera J. Finn

  • Cancer vaccines: between the idea and the reality.

    Olivera J. Finn

  • Cancer Immunology

    Unknown

  • Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

    Donna L. Barnd;Michael S. Lan;Richard S. Metzgar;Olivera J. Finn

  • Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

    Unknown

  • Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

    Keith R. Jerome;Donna L. Barnd;Katharine M. Bendt;Cinda M. Boyer

  • Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients

    Y Kotera;J D Fontenot;G Pecher;R S Metzgar

  • MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines

    Olivera J. Finn;Keith R. Jerome;Robert A. Henderson;Gabriele Pecher

  • A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

    James S. Goydos;Elaine Elder;Theresa L. Whiteside;Olivera J. Finn

  • MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study

    Takashi Kimura;John R. McKolanis;Lynda A. Dzubinski;Kazi Islam

  • MCF7 Side Population Cells with Characteristics of Cancer Stem/Progenitor Cells Express the Tumor Antigen MUC1

    Katja Engelmann;Hongmei Shen;Olivera J. Finn

  • Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

    C G Ioannides;B Fisk;K R Jerome;T Irimura

  • The dawn of vaccines for cancer prevention

    Olivera J. Finn

  • Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.

    Keith R. Jerome;Nieves Domenech;Olivera J. Finn

  • Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

    Ramesh K. Ramanathan;Kenneth M. Lee;John McKolanis;Elizabeth Hitbold

  • Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.

    Anda M. Vlad;Stefan Muller;Mare Cudic;Hans Paulsen

  • A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors

    Andrew J Lepisto;Arthur J Moser;Herbert Zeh;Kenneth Lee

  • MUC1 Immunobiology: From Discovery to Clinical Applications

    Unknown

  • IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells

    Qianting Yang;Gang Li;Gang Li;Yibei Zhu;Yibei Zhu;Lin Liu

  • Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection

    M. Melina Soares;Vinay Mehta;Olivera J. Finn

  • The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells

    Elizabeth M. Hiltbold;Anda M. Vlad;Pawel Ciborowski;Simon C. Watkins

  • Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin.

    N Doménech;R A Henderson;O J Finn

Frequent Co-Authors

Robert E. Schoen
Robert E. Schoen University of Pittsburgh
Theresa L. Whiteside
Theresa L. Whiteside University of Pittsburgh
Walter J. Storkus
Walter J. Storkus University of Pittsburgh
Michael T. Lotze
Michael T. Lotze University of Pittsburgh
Franz-Georg Hanisch
Franz-Georg Hanisch University of Cologne
Simon C. Watkins
Simon C. Watkins University of Pittsburgh
Daniel W. Cramer
Daniel W. Cramer Brigham and Women's Hospital
Ronald C. Montelaro
Ronald C. Montelaro University of Pittsburgh
Joyce Taylor-Papadimitriou
Joyce Taylor-Papadimitriou King's College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare fields can broaden career opportunities. Many professionals transition into nursing roles after building a strong science foundation. Those seeking swift entry into nursing might consider accelerated nursing programs, which offer a faster route to becoming a registered nurse.

Alternatively, starting with direct patient care roles like a Licensed Practical Nurse can be an excellent pathway. Programs labeled as easy lpn programs to get into simplify the admission process, helping candidates quickly begin hands-on nursing careers without exhaustive prerequisites.

Advancing beyond LPN roles, aspiring Advanced Practice Registered Nurses can benefit from easiest np programs to get into. These programs provide the necessary education to become nurse practitioners, enhancing scope of practice and professional autonomy.

Specializing in psychiatric care is another promising direction. The top online pmhnp programs offer excellent clinical placement rates, which are critical for gaining hands-on experience in mental health nursing while completing a degree online.

Best Scientists Citing Olivera J. Finn

Trending Scientists